Aquestive Therapeutics, Inc.
United States · Biopharma, Biotechnology, Healthcare
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headqua
Key facts
- Headquarters
- United States
- Employees
- 150
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (AQST)
- Website
- aquestive.com
Recent activity at Aquestive Therapeutics, Inc.
- : Richard J. Daly Appointed as Director of Aquestive Therapeutics
- : SEC 8-K (5.02): On September 29, 2026, Aquestive Therapeutics, Inc. announced that Richard J. Daly has been elected as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term that will expire at the Company's 2028 Annual Meeting of Stockholders. The announcement regarding Mr. Daly's election was made through a press release on the same date, highlighting a strategic move by the Board of Directors to strengthen its governance. This change reflects the Company's ongoing efforts to enhance leadership and oversight.
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. is providing a Regulation FD Disclosure in connection with an investor presentation to be held on September 23, 2026. This presentation includes information intended for institutional investors and analysts, and aims to update stakeholders on the company's developments and strategies. A copy of the investor presentation is available on the company's website, reflecting its commitment to transparency in communications with investors.
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. provided a Regulation FD disclosure regarding an investor presentation during the H.C. Wainwright 28th Annual Global Investor Conference held on September 14, 2026. This presentation was aimed at institutional investors, analysts, and others to share significant updates about the company. The event included insights into the company's operations and future strategies. The presentation could potentially influence investor perception and decision-making regarding the company's stock. A copy of the presentation is attached as Exhibit 99.2 in this filing.
- : SEC 8-K (7.01): On August 10, 2026, Aquestive Therapeutics, Inc. provided an investor presentation for meetings with institutional investors and analysts. This presentation is aimed at communicating important company information and may be amended or updated through subsequent filings. The presentation emphasizes the company's strategic initiatives and future direction, impacting its visibility in the market and investor relations. The presentation is accessible online at the company's investor relations website, with availability subject to change.
- : SEC 8-K (7.01): On March 30, 2026, Aquestive Therapeutics, Inc. announced the successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) concerning the resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, intended for the treatment of Type 1 allergic reactions, including anaphylaxis. The receipt of preliminary comments from the FDA is a significant step in the approval process for this drug, highlighting the company's ongoing efforts to address critical medical needs in allergy treatment. The event dated today indicates urgency in securing the necessary approvals to move forward with this product.
- : Aquestive Therapeutics Announces Departure of Chief Legal Officer
- : SEC 8-K (5.02): On March 16, 2026, Aquestive Therapeutics, Inc. announced the departure of its Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary, Lori J. Braender. Her resignation from the Chief Legal Officer and Chief Compliance Officer roles will be effective April 2, 2026, although she will remain with the company to provide transition services and will continue to receive her current base salary until May 7, 2026. Furthermore, she will continue to serve as the Corporate Secretary through at least the end of the year. This transition indicates a strategic shift within the company's leadership as it seeks to possibly restructure its legal and compliance oversight.
- : Aquestive Therapeutics Extends Marketing Approval Deadline and Issues Warrant to RTW Investments
- : SEC 8-K (1.01): On March 3, 2026, Aquestive Therapeutics, Inc. entered into Amendment No. 1 to the Purchase and Sale Agreement with RTW Investments, LP, extending the Marketing Approval Deadline to June 30, 2027. Additionally, the Company issued a warrant to RTW allowing the purchase of 375,000 shares of its common stock at an exercise price of $4.00 per share, expiring on March 3, 2029. These agreements are significant as they may impact the Company's financing and strategic direction regarding product marketing approvals and investor relations.
Aquestive Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2018 | Venture | $9.1M |
Leadership
- Milosz Blyszczek, Senior Director Clinical Operations
- Santo Costa, Director
- James Scibetta, Director
- John Cochran, Director
- Gregory Brown, Director
- Douglas Bratton, Director
- A. Shobel, Executive Officer, Director
- Keith Kendall, Executive Officer, Director
- Richard J. Daly, Director
- Lori J. Braender, Chief Compliance Officer
- Matthew Greenhawt, Chief Medical Officer
- Theresa Wood, Executive Officer
Verified email and direct lines for Aquestive Therapeutics, Inc.’s decision-makers are on Fundz. See plans
Employee benefit plans
Aquestive Therapeutics, Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Aquestive Therapeutics, Inc. in the news
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly - GlobeNewswire (Sep 29, 2026)
- Aquestive Therapeutics Announces Resubmission of New Drug - GlobeNewswire (Sep 17, 2026)
- Aquestive Therapeutics Announces Regulatory Development for Anaphylm Sublingual Film and Provides Business Update - Investing News Network (Jan 09, 2026)
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky - PR Newswire (Apr 22, 2026)
- Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET - The Manila Times (Jul 29, 2026)
- Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewswire (Sep 01, 2026)
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt - PR Newswire (Apr 30, 2026)
- AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire (Apr 07, 2026)
Companies similar to Aquestive Therapeutics, Inc.
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Pharmaceutical, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- NRx Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Citius Oncology · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Aquestive Therapeutics, Inc.: questions and answers
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headqua
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc. is headquartered in United States.
How many employees does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has about 150 employees.
Has Aquestive Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 1 funding event for Aquestive Therapeutics, Inc.. The most recent, $9.1M, was in May 2018.
What is the latest news on Aquestive Therapeutics, Inc.?
On Sep 29, 2026, Richard J. Daly Appointed as Director of Aquestive Therapeutics
Is Aquestive Therapeutics, Inc. a public company?
Yes. Aquestive Therapeutics, Inc. is publicly traded under the ticker AQST.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy